Wagner L, Isbrucker R, Locht C, Arciniega J, Costanzo A, McFarland R, Oh H, Hoonakker M, Descamps J, Andersen S R, Gupta R K, Markey K, Chapsal J M, Lidster K, Casey W, Allen D
US FDA.
Health Canada.
Pharmeur Bio Sci Notes. 2016;2016:151-170.
The 'International Workshop on Alternatives to the Murine Histamine Sensitization Test for Acellular Pertussis Vaccines: In Search of Acceptable Alternatives to the Murine Histamine Sensitization Test (HIST): What is Possible and Practical?' was held on 4 and 5 March 2015 in London, United Kingdom. Participants discussed the results of the data generated from an international collaborative study (BSP114 Phase 2) sponsored by the European Directorate for the Quality of Medicines & Health Care (EDQM) to determine if a modified Chinese hamster ovary (CHO) cell-based clustering assay is a suitable alternative to replace HIST. Workshop participants agreed that protocol transferability demonstrated in the collaborative study indicates that a standardised CHO cell assay is adequate for measuring pure PTx in reference preparations. However, vaccine manufacturers would still need to demonstrate that the method is valid to detect or measure residual PTx in their specific adjuvanted products. The 2 modified CHO cell protocols included in the study (the Direct and the Indirect Methods) deserve further consideration as alternatives to HIST. Using the CHO cell assay, an in vitro alternative, for acellular pertussis (aP) vaccine batch release testing would reduce the number of animals used for aP vaccine safety testing. A strategic, stepwise adoption plan was proposed, in which the alternative test would be used for release purposes first, and then, once sufficient confidence in its suitable performance has been gained, its use would be extended to stability testing.
“无细胞百日咳疫苗鼠组胺致敏试验替代方法国际研讨会:探寻鼠组胺致敏试验(HIST)的可接受替代方法:哪些可行且实用?”于2015年3月4日至5日在英国伦敦举行。与会者讨论了由欧洲药品质量管理局(EDQM)赞助的一项国际合作研究(BSP114第二阶段)所产生的数据结果,以确定改良的基于中国仓鼠卵巢(CHO)细胞的聚类试验是否是替代HIST的合适方法。研讨会参与者一致认为,合作研究中展示的方案可转移性表明,标准化的CHO细胞试验足以测量参考制剂中的纯PTx。然而,疫苗制造商仍需证明该方法对于检测或测量其特定佐剂产品中的残留PTx是有效的。该研究中包含的2种改良CHO细胞方案(直接法和间接法)作为HIST的替代方法值得进一步考虑。使用CHO细胞试验这种体外替代方法进行无细胞百日咳(aP)疫苗批放行检测,将减少用于aP疫苗安全性检测的动物数量。会上提出了一项战略性的逐步采用计划,即该替代试验首先用于放行目的,然后,一旦对其合适性能获得足够信心,其用途将扩展至稳定性检测。